Open Nav

Ab Studio Inc.

  • Yue Liu, Ab Studio Inc.

Introduce our technology platforms and leading products

  • Date:Wednesday, October 17
  • Time:10:15 AM - 10:30 AM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Ab Studio Inc. is a technology platform company developing novel therapeutic antibodies with the following unique technologies: 1) "Imbalanced" bispecific antibody platform 2) "Serial" internalizing antibody platform. We deeply believe in "quality by design" rule and would like to contribute to the therapeutic antibody R&D field via CRO service, partnership and licensing out. Our lead program, a computational designed CD20/CD3 "imbalanced" bispecific antibody (bsAb) has significantly reduced CD3 binding affinity and high CD20 binding affinity. In vitro data showed that this bsAb "safely" maintains the effector function and has less potential to trigger cytokine storm while still has good efficacy, this bsAb also has good develop-ability due to computational optimization design. We look forward to partnering with Biopharmas to co-develop this leading program, other pipeline programs and/or to co-develop novel therapeutic antibodies with our proven technology platforms.
  • Company
  • Company HQ City:Hayward, CA
  • Company HQ Country:United States
  • Company HQ State:Delaware                    
  • CEO/Top Company Official:Yue Liu, Ph.D.
  • Year Founded:2017
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :CD20/CD3 "imbalanced" bispecific antibody
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :2
  • Previous and Current Investors:Bridge pharm
  • Size of Last Investment Round:one million
  • Total Amount Raised to Date, In All Rounds:one million
Yue Liu
Ab Studio Inc.